EcoDrugPlus

Phosphodiesterase 3a

Ensembl ID : ENSCLAG00000015697
Gene Symbol: PDE3A
3 Cross references
258 Possible Orthologues:

Phosphodiesterase 3b

Ensembl ID : ENSCLAG00000016912
Gene Symbol: PDE3B
2 Cross references
204 Possible Orthologues:

Phosphodiesterase 4a

Ensembl ID : ENSCLAG00000005445
Gene Symbol: PDE4A
2 Cross references
250 Possible Orthologues:

Phosphodiesterase 4b

Ensembl ID : ENSCLAG00000006409
Gene Symbol: PDE4B
2 Cross references
298 Possible Orthologues:

Phosphodiesterase 4c

Ensembl ID : ENSCLAG00000016330
Gene Symbol: PDE4C
2 Cross references
89 Possible Orthologues:

Phosphodiesterase 4d

Ensembl ID : ENSCLAG00000006363
Gene Symbol: PDE4D
3 Cross references
235 Possible Orthologues:

Phosphodiesterase 5a

Ensembl ID : ENSCLAG00000004806
Gene Symbol: PDE5A
3 Cross references
208 Possible Orthologues:

Phosphodiesterase 7a

Ensembl ID : ENSCLAG00000001879
Gene Symbol: PDE7A
2 Cross references
240 Possible Orthologues:

Phosphodiesterase 7b

Ensembl ID : ENSCLAG00000007039
Gene Symbol: PDE7B
3 Cross references
174 Possible Orthologues:

Phosphodiesterase 9a

Ensembl ID : ENSCLAG00000005531
Gene Symbol: PDE9A
2 Cross references
193 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 1

Ensembl ID : ENSCLAG00000003755
Gene Symbol: PIK3R1
2 Cross references
259 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 2

Ensembl ID : ENSCLAG00000014107
Gene Symbol: PIK3R2
2 Cross references
253 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).